Sameera Tak & Catherine Chamoux How can Field Market Access teams be partners in Excellence to its medical and commercial functions? Sameera Tak & Catherine
GAVIN OUTTERIDGE Why it makes sense to opt for a Joint Scientific Consultation GAVIN OUTTERIDGE & CATHERINE CHAMOUX “Even though there are no ways of
Sameera Tak Facing Biosimilar Competition: Value & Access Readiness Strategies Sameera Tak Biosimilars Loss of exclusivity is notorious for giving pharma and biotech executives sleepless
GAVIN OUTTERIDGE How biopharma innovators can benefit from the ACCESS Consortium and CAN/UK/AUS collaboration in HTA GAVIN OUTTERIDGE & BOB CLAY What’s happening now, across
GAVIN OUTTERIDGE The European Union’s new Health Technology Assessment (HTA) Regulation demands that innovative biotech and pharma companies submit a new type of value dossier